Explore the words cloud of the FuseX project. It provides you a very rough idea of what is the project "FuseX" about.
The following table provides information about the project.
EIO BIOMEDICAL LTD
|Coordinator Country||Israel [IL]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-08-01 to 2018-11-30|
Take a look of project's partnership.
|1||EIO BIOMEDICAL LTD||IL (NAZARETH)||coordinator||50˙000.00|
Surgical adhesions are a consequence of abdominal trauma during surgery. Although there are a multitude of available barriers on the market today, the efficacy of these solutions is still in question and can lead to adverse side effects. If untreated, these surgical adhesions can solidify and grow, potentially leading to infertility, chronic pain, and difficulties in repeat operations. To address adhesions, patients must undergo additional abdominal surgery, putting unnecessary stress on existing healthcare systems. On average, 35% of patients who undergo open abdominal or pelvic surgery are readmitted twice in the following 10 years due to complications. EIO Biomedical has developed a revolutionary anti-adhesion system in order to eliminate initial formation of surgical adhesions. The FuseX system, delivers a mixture of donor blood plasma with a concentrated mix of natural coagulation factors found in the blood. This results in less post-surgical adhesions, and related complications, and translates to an estimated 6-12 B€ in saved expenses per year. Preliminary testing of the material demonstrated a 60-90% reduction of adhesions, depending on the severity, whilst the non-invasive laparoscopic application also reduced open wound size and extent of trauma. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Within the overall innovation project, EIO Biomedical is set to initiate safety and efficiency trials in Lithuania and Spain, where they will initially market their product. After initial testing, device function and efficiency will be further improved to enable a more rapid procedure for scale up to commercialization. Post-commercialization, CEO Dr. Yair Pilpel hopes to integrate anti-inflammatories, pain killers, and antibiotics, into the solution for widespread use in hospitals, clinics, and potentially schools.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FUSEX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FUSEX" are provided by the European Opendata Portal: CORDIS opendata.
Standardised administration device for raw medical herbsRead More
MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINERead More
Pole climbing solution to improve safety at work and to prevent fatal accidents in industrial climbingRead More